Cytosorbents (CTSO) Revenue Growth (1y) (2012 - 2026)
Cytosorbents (CTSO) Revenue Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn | 16.70% |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 7.41% |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | 15.05% |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn | 6.08% |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn | 1.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.57% |
| Dec 31, 2025 | 0.91% |
| Sep 30, 2025 | 10.12% |
| Jun 30, 2025 | 8.76% |
| Mar 31, 2025 | -2.92% |
| Dec 31, 2024 | 5.57% |
| Sep 30, 2024 | -2.25% |
| Jun 30, 2024 | -6.14% |
| Mar 31, 2024 | -4.87% |
| Dec 31, 2023 | -7.69% |
| Sep 30, 2023 | 8.62% |
| Jun 30, 2023 | 10.89% |
| Mar 31, 2023 | 8.72% |
| Dec 31, 2022 | -12.91% |
| Sep 30, 2022 | -16.90% |
| Jun 30, 2022 | -29.35% |
| Mar 31, 2022 | -18.00% |
| Dec 31, 2021 | -9.82% |
| Sep 30, 2021 | -7.45% |
| Jun 30, 2021 | 22.76% |